|
|
One Edwards Way Irvine, CA 92614 USA phone:(949) 250-5070 fax:(949) 250-2733 |
| Symbol |
EW |
| Exchange |
NYSE |
| Founded |
1958 |
| Employees |
6300 |
|
|
| www.edwards.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Heart valves and hemodynamic monitoring |
 |
| Management |
| Michael A. Mussallem, Chairman and Chief Executive Officer; Donald E. Bobo, Jr., Corporate Vice President, Heart Valve Therapy; Thomas M. Abate, Corporate Vice President, Chief Financial Officer & Treasurer; Bruce P. Garren, Corporate Vice President, Government Affairs & General Counsel; John P. McGrath, Corporate Vice President, Quality |
|
|
|
|
| Keywords |
| heart valve therapy, cardiac, vascular, investigational, transcatheter |
|
|
|
|
| Description |
|
Edwards Lifesciences (NYSE: EW) is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, California, Edwards has more than 6,200 employees worldwide, selling medical technologies in nearly 100 countries with 2008 sales of $1.24 billion. Eighty-five percent of the company’s sales come from brands with leading global market positions, including Carpentier-Edwards, Cosgrove-Edwards, Fogarty, PERIMOUNT and Swan-Ganz. Edwards Lifesciences leverages its research, design, development and marketing expertise to produce products that address specific cardiovascular opportunities including heart valve disease, vascular disease and critical care technologies. |
 |
| Products / Services |
Products address specific cardiovascular opportunities including heart valve disease and critical care technologies.
|
 |
| Market / Customers |
More than ninety percent of the company's sales come from brands with leading global market positions, including Carpentier-Edwards, Cosgrove-Edwards, Fogarty, PERIMOUNT and Swan-Ganz.
|
 |
|
|
|
|